toripalimab
coherus biosciences,shanghai junshi bioscience
['toripalimab', 'polaris-03', 'biomarker', 'urothelial']
toripalimab (anti-pd-1) monotherapy as a second-line treatment for patients with metastatic #urothelialcarcinoma (polaris-03): two-year survival update and biomarker analysis. presented by haige chen. #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology